UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020358
Receipt number R000023516
Scientific Title Preliminary study on recombinant human soluble thrombomodulin (rTM) administration for treatment of pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection
Date of disclosure of the study information 2015/12/28
Last modified on 2019/03/29 06:17:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Preliminary study on recombinant human soluble thrombomodulin (rTM) administration for treatment of pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection

Acronym

Recombinant human soluble thrombomodulin (rTM) for treatment of pneumonia-induced ARDS complicated with DIC and sepsis, including avian influenza virus infection

Scientific Title

Preliminary study on recombinant human soluble thrombomodulin (rTM) administration for treatment of pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection

Scientific Title:Acronym

Recombinant human soluble thrombomodulin (rTM) for treatment of pneumonia-induced ARDS complicated with DIC and sepsis, including avian influenza virus infection

Region

Asia(except Japan)


Condition

Condition

Pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection

Classification by specialty

Pneumology Infectious disease Pediatrics
Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To observe the clinical course and change of plasma thrombomodullin concentration after administration of rTM for treating pneumonia-induced ARDS complicated with DIC and sepsis, including avian influenza virus infection.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change of plasma thrombomodullin concentration

Key secondary outcomes

1. Observation of clinical course
1.1. Status of DIC
(1) DIC score(ISTH)
(2) Bleeding symptoms
(3) Vital signs and physical examination findings
(4) Other laboratory findings; e.g. proinflammatory cytokines
1.2. Status of ARDS
(1) P/F ratio
(2) Duration of fever
(3) Duration of mechanical ventilation including CPAP
(4) Vital signs, physical examination findings and SpO2
(5) Chest X ray findings
Extent of infiltration: 0=No infiltration, 1=Unilateral, 2=bilateral
(6) Other laboratory findings; e.g. blood gas analysis
1.3. The change of liver function and renal function
2. Outcome
3. The etiology of pneumonia-induced ARDS complicated with DIC and sepsis


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Drip infusion of 380 U/kg of rTM q24 hours for maximum 6 days.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 months-old <=

Age-upper limit

180 months-old >=

Gender

Male and Female

Key inclusion criteria

1.Severe ARDS complicated with DIC and sepsis. Patients who fulfill all of the followings (1-5) within 72 hours from PICU admission
1) The patients who admitted the PICU-NHP
2) Age: 1 month -15 years old
3) DIC score is within ISTH DIC criteria (Score 5 or more).
4) PaO2/FiO2 ratio (P/F ratio) less than 100 mmHg in arterial blood gas analysis.
5) No severe left ventricular dysfunction
6) Chest X ray abnormal shadow (consolidation, ground-glass opacity, or nodular shadow)
7) Patients provide written informed consent prior to initiation of any study procedures. Patients who or whose attorney are able to understand and comply with planned study procedures.

2.Avian influenza virus infection induced ARDS complicated with DIC and sepsis. Patients who fulfill all of the followings (1-9) within 72 hours from PICU admission
1) Contact with sick or dead poultry
2) Positive result of rapid diagnostic test for influenza A, or avian influenza viral genomes are positive with PCR.
3) Patients with 2 or more of the following symptoms.
Fever, Cough, Dyspnea, Sore throat, Nasal congestion or rhinorrhea, Headache, Myalgia or arthralgia
4) The patients who admitted the PICU-NHP
5) Age: 1 month -15 years old
6) DIC score is within ISTH DIC criteria (Score more more than 5)
7) PaO2/FiO2 ratio (P/F ratio) less than 300 mmHg in arterial blood gas analysis
8) Chest X ray abnormal shadow (consolidation, ground-glass opacity, or nodular shadow)
9) Patients provide written informed consent prior to initiation of any study procedures. Patients who or whose attorney are able to understand and comply with planned study procedures.

Key exclusion criteria

Patients who fulfill any of the followings are excluded
1. Patients with severe renal dysfunction (creatinine clearance < 10mL/min)
2. Patients with bleeding symptoms.
3. Patients whom the treating doctor deems, for any reason, to be ineligible.

Target sample size

3


Research contact person

Name of lead principal investigator

1st name Noriko
Middle name
Last name Nakajima

Organization

National Institute of Infectious diseases

Division name

department of pathology

Zip code

1628640

Address

Toyama 1-23-1, Shinjuku-ku, Tokyo, 162-8640, Japan

TEL

+81-2-5285-1111

Email

tenko@nih.go.jp


Public contact

Name of contact person

1st name Jin
Middle name
Last name Takasaki

Organization

National Center for Global Health and Medicine

Division name

Department of respiratory medicine

Zip code

1628655

Address

Toyama 1-21-1, Shinjuku-ku, Tokyo, 162-8655, Japan

TEL

+81-3-3202-7181

Homepage URL


Email

jintakajj@gmail.com


Sponsor or person

Institute

National Hospital for Pediatrics, Nanoi, Vietnam

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics committee NCGM

Address

1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan

Tel

+81-3-3202-7181

Email

rinrijm@hosp.ncgm.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 12 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 08 Month 24 Day

Date of IRB

2015 Year 08 Month 24 Day

Anticipated trial start date

2015 Year 12 Month 29 Day

Last follow-up date

2018 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 12 Month 26 Day

Last modified on

2019 Year 03 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023516


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name